Drug Safety

, Volume 28, Issue 4, pp 351–370 | Cite as

Hepatic Findings in Long-Term Clinical Trials of Ximelagatran

  • William M. Lee
  • Dominique Larrey
  • Rolf Olsson
  • James H. Lewis
  • Marianne Keisu
  • Laurent Auclert
  • Sunita Sheth
Original Research Article


Objective: In clinical trials, the efficacy and safety of the oral direct thrombin inhibitor ximelagatran have been evaluated in the prevention or treatment of thromboembolic conditions known to have high morbidity and mortality. In these studies, raised aminotransferase levels were observed during long-term use (>35 days). The aim of this analysis is to review the data regarding these hepatic findings in the long-term trials of ximelagatran.

Patients and methods: The prospective analysis included 6948 patients randomised to ximelagatran and 6230 patients randomised to comparator (warfarin, low-molecular weight heparin followed by warfarin or placebo). Of these, 6931 patients received ximelagatran for a mean of 357 days and 6216 patients received comparator for a mean of 389 days. An algorithm was developed for frequent testing of hepatic enzyme levels. A panel of four hepatologists analysed all cases of potential concern with regard to causal relation to ximelagatran treatment using an established evaluation tool (Roussel Uclaf Causality Assessment Method [RUCAM]).

Results: An elevated alanine aminotransferase (ALT) level of >3 × the upper limit of normal (ULN) was found in 7.9% of patients in the ximelagatran group versus 1.2% in the comparator group. The increase in ALT level occurred 1–6 months after initiation of therapy and data were available to confirm recovery of the ALT level to <2 × ULN in 96% of patients, whether they continued to receive ximelagatran or not. There was some variability in the incidence of ALT level elevation between indications, those with simultaneous acute illnesses (acute myocardial infarction or venous thromboembolism) having higher incidences. Combined elevations of ALT level of >3 × ULN and total bilirubin level of >2 × ULN (within 1 month of the ALT elevation), regardless of aetiology, were infrequent, occurring in 37 patients (0.5%) treated with ximelagatran, of whom one sustained a severe hepatic illness that appeared to be resolving when the patient died from a gastrointestinal haemorrhage. No death was observed directly related to hepatic failure caused by ximelagatran.

Conclusion: Treatment with ximelagatran has been associated with mainly asymptomatic elevation of ALT levels in a mean of 7.9% of patients in the long-term clinical trial programme and nearly all of the cases occurred within the first 6 months of therapy. Rare symptomatic cases have been observed. An algorithm has been developed for testing ALT to ensure appropriate management of patients with elevated ALT levels. Regular ALT testing should allow the clinical benefits of ximelagatran to reach the widest population of patients while minimising the risk of hepatic adverse effects.


Total Bilirubin Level Atrial Fibrillation Group Oral Direct Thrombin Inhibitor Hepatic Enzyme Level Bilirubin Level Elevation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this study. W.M. Lee; D. Larrey. R. Olsson and J.H. Lewis are consultants to AstraZeneca and comprise the Data and Safety Monitoring Board for Exanta®. M. Keisu; L. Auclert and S. Sheth are employed by AstraZeneca. Writing assistance was provided by PAREXEL MMS.


  1. 1.
    Andrejak M, Gras V. Drugs affecting blood clotting, fibrinolysis, and hemostasis. In: Dukes MNG, Aronson JK, editors. Meyler’s side effects of drugs. 14th ed. Oxford: Elsevier, 2000: Chap 35.1Google Scholar
  2. 2.
    Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119(1 Suppl.): 8S–21SPubMedCrossRefGoogle Scholar
  3. 3.
    Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119Suppl. 1: 22S–38SPubMedCrossRefGoogle Scholar
  4. 4.
    Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002; 25: 447–54PubMedCrossRefGoogle Scholar
  5. 5.
    Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41–6PubMedCrossRefGoogle Scholar
  6. 6.
    Wahlander K, Lapidus L, Olsson CG, et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002; 107: 93–9PubMedCrossRefGoogle Scholar
  7. 7.
    Wolzt M, Wollbratt M, Svensson M, et al. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 2003; 59: 537–43PubMedCrossRefGoogle Scholar
  8. 8.
    Grind M, Hamren B, Baathe S, et al. Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation receiving long-term treatment: a population analysis by nonlinear mixed effect modeling [abstract]. Clin Pharmacol Ther 2002; 71: 31Google Scholar
  9. 9.
    Fiessinger J-N, Huisman MV, Davidson BL, et al. for the THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681–9PubMedCrossRefGoogle Scholar
  10. 10.
    Schulman S, Wåhlander K, Lundström T, et al. for the THRIVE III Investigators. Extended secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation. N Engl J Med 2003; 349: 1713–21PubMedCrossRefGoogle Scholar
  11. 11.
    Petersen P, Grind M, Adler J, et al. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003; 41: 1445–51PubMedCrossRefGoogle Scholar
  12. 12.
    Petersen P. A two-year follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke in patients with nonvalvular atrial fibrillation [abstract]. Neurology 2002; 58Suppl. 3: A477Google Scholar
  13. 13.
    Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691–8PubMedCrossRefGoogle Scholar
  14. 14.
    SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690–8Google Scholar
  15. 15.
    Wallentin L, Wilxcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet 2003; 362: 789–97PubMedCrossRefGoogle Scholar
  16. 16.
    Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452–63PubMedGoogle Scholar
  17. 17.
    White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107Suppl. 1: I4–8PubMedGoogle Scholar
  18. 18.
    Prandoni P, Lensing AW, Prins MR. Long-term outcomes after deep venous thrombosis of the lower extremities. Vasc Med 1998; 3: 57–60PubMedGoogle Scholar
  19. 19.
    Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119(1 Suppl.): 176S–93SPubMedCrossRefGoogle Scholar
  20. 20.
    Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760–4PubMedCrossRefGoogle Scholar
  21. 21.
    Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492–501PubMedGoogle Scholar
  22. 22.
    Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119(1 Suppl.): 194S–206SPubMedCrossRefGoogle Scholar
  23. 23.
    Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001; 22: 1852–923PubMedCrossRefGoogle Scholar
  24. 24.
    FDA Clinical White Paper, November 2000. CDER-PhRMAAASLD Conference 2000. Drug-induced liver injury: a national and global problem [online]. Available from URL: [Accessed 2003 Dec 8]
  25. 25.
    Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89: 288–96PubMedGoogle Scholar
  26. 26.
    Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490–6PubMedCrossRefGoogle Scholar
  27. 27.
    Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002; 137: 648–55PubMedGoogle Scholar
  28. 28.
    Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703–12PubMedCrossRefGoogle Scholar
  29. 29.
    Colwell CW, Berkowitz SD, Comp PC, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for prevention of venous thromboembolism after total knee replacement. J Bone Joint Surg Am. In pressGoogle Scholar
  30. 30.
    Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer disease. JAMA 1994; 271: 992–8PubMedCrossRefGoogle Scholar
  31. 31.
    Lednar W, Lemon S, Kirkpatrick J, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985; 122: 226–33PubMedGoogle Scholar
  32. 32.
    Danan G, Benichou C. Causality assessment of adverse reactions to drugs: I. a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323–30PubMedCrossRefGoogle Scholar
  33. 33.
    Benichou Q Danan G, Flahault A. Causality assessment of adverse reactions to drugs: II. an original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331–6PubMedCrossRefGoogle Scholar
  34. 34.
    Lee WM. Assessing causality in drug-induced liver injury. J Hepatol 2000; 33: 1003–5PubMedCrossRefGoogle Scholar
  35. 35.
    Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308–10PubMedCrossRefGoogle Scholar
  36. 36.
    Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145–55PubMedCrossRefGoogle Scholar
  37. 37.
    Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272–6PubMedCrossRefGoogle Scholar
  38. 38.
    Lafata JE, Martin SA, Kaatz S, et al. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000; 15: 31–7PubMedCrossRefGoogle Scholar
  39. 39.
    Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–9PubMedCrossRefGoogle Scholar
  40. 40.
    Hollowell J, Ruigomez A, Johansson S, et al. The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom. Br J Gen Pract 2003: 53: 312–4PubMedGoogle Scholar
  41. 41.
    Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004; 164: 2044–50PubMedCrossRefGoogle Scholar
  42. 42.
    Mohi-ud-din R, Lewis JH. Drug- and chemical-induced cholestasis. Clin Liver Dis2004 2004; 8: 95–132CrossRefGoogle Scholar
  43. 43.
    Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474–85PubMedCrossRefGoogle Scholar
  44. 44.
    Dossing M, Sonne J. Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf 1993; 9: 441–9PubMedCrossRefGoogle Scholar
  45. 45.
    Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 1st ed. Chapter 16: Drug-induced liver disease. New York: Appleton-Century-Crofts, 1978Google Scholar
  46. 46.
    Senior J. Regulatory perspectives. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. New York: Marcel Dekker, 2003: 739–54Google Scholar
  47. 47.
    Yeo W, Chan PKS, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299–307PubMedCrossRefGoogle Scholar
  48. 48.
    McNeill L, Allen M, Estrada C et al. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003; 123: 102–6PubMedCrossRefGoogle Scholar
  49. 49.
    Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case study. Am J Med 2003; 114: 299–306PubMedCrossRefGoogle Scholar
  50. 50.
    Lewis JH. Drug-induced liver disease. Med Clin North Am 2000; 84: 1275–311PubMedCrossRefGoogle Scholar
  51. 51.
    Gurewich V. Ximelagatran: promises and concerns. JAMA 2005; 293: 736–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • William M. Lee
    • 1
  • Dominique Larrey
    • 2
  • Rolf Olsson
    • 3
  • James H. Lewis
    • 4
  • Marianne Keisu
    • 5
  • Laurent Auclert
    • 5
  • Sunita Sheth
    • 6
  1. 1.University of Texas Southwestern Medical Center at DallasDallas, TX 75390-9151USA
  2. 2.Service Hépato-Gastroentérologie, CHU MontpellierHôpital Saint Eloi and INSERM U632MontpellierFrance
  3. 3.Sahlgrenska University HospitalGothenburgSweden
  4. 4.Georgetown University Medical CenterWashingtonUSA
  5. 5.AstraZeneca R&D MölndalMölndalSweden
  6. 6.AstraZeneca LPWilmingtonUSA

Personalised recommendations